File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Adefovir dipivoxil in chronic hepatitis B infection

TitleAdefovir dipivoxil in chronic hepatitis B infection
Authors
Issue Date2004
PublisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/eop
Citation
Expert Opinion On Pharmacotherapy, 2004, v. 5 n. 11, p. 2361-2367 How to Cite?
AbstractAdefovir dipivoxil, an acyclic nucleotide analogue, is effective for the treatment of chronic hepatitis B in both hepatitis B e antigen (HBeAg)-positive and -negative patients, with improvement in liver histology, hepatitis B virus (HBV) DNA levels, alanine aminotransferase levels, and HBeAg seroconversion (for HBeAg-positive patients). It is also effective against lamivudine-resistant strains of hepatitis B mutations. It has been studied in pre- and post-liver transplant patients. Compared to lamivudine, adefovir dipivoxil is associated with a much lower risk of emergence of drug-resistant HBV. Adefovir-associated resistant virus is susceptible to lamivudine therapy. The recommended dose of adefovir dipivoxil 10 mg is associated with low risk of nephrotoxicity. Adefovir dipivoxil can be recommended as a firs-line treatment but can also be used in patients with chronic hepatitis B infection who are failing lamivudine therapy. © 2004 Ashley Publications Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/78100
ISSN
2015 Impact Factor: 3.543
2015 SCImago Journal Rankings: 0.884
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYuen, MFen_HK
dc.contributor.authorLai, CLen_HK
dc.date.accessioned2010-09-06T07:39:10Z-
dc.date.available2010-09-06T07:39:10Z-
dc.date.issued2004en_HK
dc.identifier.citationExpert Opinion On Pharmacotherapy, 2004, v. 5 n. 11, p. 2361-2367en_HK
dc.identifier.issn1465-6566en_HK
dc.identifier.urihttp://hdl.handle.net/10722/78100-
dc.description.abstractAdefovir dipivoxil, an acyclic nucleotide analogue, is effective for the treatment of chronic hepatitis B in both hepatitis B e antigen (HBeAg)-positive and -negative patients, with improvement in liver histology, hepatitis B virus (HBV) DNA levels, alanine aminotransferase levels, and HBeAg seroconversion (for HBeAg-positive patients). It is also effective against lamivudine-resistant strains of hepatitis B mutations. It has been studied in pre- and post-liver transplant patients. Compared to lamivudine, adefovir dipivoxil is associated with a much lower risk of emergence of drug-resistant HBV. Adefovir-associated resistant virus is susceptible to lamivudine therapy. The recommended dose of adefovir dipivoxil 10 mg is associated with low risk of nephrotoxicity. Adefovir dipivoxil can be recommended as a firs-line treatment but can also be used in patients with chronic hepatitis B infection who are failing lamivudine therapy. © 2004 Ashley Publications Ltd.en_HK
dc.languageengen_HK
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/eopen_HK
dc.relation.ispartofExpert Opinion on Pharmacotherapyen_HK
dc.rightsExpert Opinion on Pharmacotherapy. Copyright © Informa Healthcare.en_HK
dc.subject.meshAdenine - analogs & derivatives - pharmacokinetics - therapeutic useen_HK
dc.subject.meshAnimalsen_HK
dc.subject.meshAntiviral Agents - pharmacokinetics - therapeutic useen_HK
dc.subject.meshClinical Trials as Topicen_HK
dc.subject.meshDrug Resistance, Viral - geneticsen_HK
dc.subject.meshHepatitis B e Antigens - blooden_HK
dc.subject.meshHepatitis B virus - drug effects - geneticsen_HK
dc.subject.meshHepatitis B, Chronic - drug therapy - immunologyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshLamivudine - therapeutic useen_HK
dc.subject.meshPhosphonic Acids - pharmacokinetics - therapeutic useen_HK
dc.titleAdefovir dipivoxil in chronic hepatitis B infectionen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1465-6566&volume=5&issue=11&spage=2361&epage=7&date=2004&atitle=Adefovir+dipivoxil+in+chronic+hepatitis+B+infectionen_HK
dc.identifier.emailYuen, MF:mfyuen@hkucc.hku.hken_HK
dc.identifier.emailLai, CL:hrmelcl@hku.hken_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1517/14656566.5.11.2361en_HK
dc.identifier.pmid15500383-
dc.identifier.scopuseid_2-s2.0-8544261146en_HK
dc.identifier.hkuros101393en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-8544261146&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume5en_HK
dc.identifier.issue11en_HK
dc.identifier.spage2361en_HK
dc.identifier.epage2367en_HK
dc.identifier.isiWOS:000224944600017-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats